title: High dialysate flow rate continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome.
abstract: A continuous dialysis technique such as continuous arteriovenous hemodialysis (CAVHD) could be an interesting alternative to frequent intermittent hemodialysis to treat acute renal failure (ARF) secondary to tumor lysis syndrome (TLS). However, because of massive release of intracellular solutes in TLS, CAVHD clearances need to be increased to treat this syndrome. Continuous arteriovenous hemodialysis using a high dialysate flow rate at 4 L/hr was assessed in TLS and ARF associated with severe hyperphosphatemia. A 0.6-m2 hollow-fiber polyacrylonitrile dialyzer (Multiflow 60; Hospal, St-Léonard, Québec, Canada) was used. Blood urea nitrogen and serum creatinine levels decreased, respectively, from 102.5 to 27.2 mg/dL and from 3.1 to 1.8 mg/dL during the 36 hours of treatment. Serum urate concentration was normal at the beginning of treatment (4.5 mg/dL) and decreased to 2.1 mg/dL by the end of CAVHD. Serum phosphorus decreased from 16.7 to 4.4 mg/dL after the 36 hours of treatment. The calcium x phosphorus product decreased from 111.1 to 42.1 by 28 hours and remained under 50 thereafter. Serum potassium was easily controlled with the addition of 2.5 mEq/L of KCl in dialysate and replacement solutions. No rebound increases in phosphorus or potassium were noted after cessation of therapy. Continuous arteriovenous hemodialysis clearances of urea, creatinine, phosphorus, and urate were measured at 2-hour intervals for the first 24 hours and at 4-hour intervals for the remaining 12 hours. They were 53.0 +/- 2.3 mL/min, 43.7 +/- 2.2 mL/min, 40.4 +/- 1.9 mL/min, and 39.3 +/- 1.9 mL/min (n = 15), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Néphrologie, Hôpital Maisonneuve-Rosemont, Université de Montréal, Québec, Canada.
authors.forename: V
authors.initials: V
authors.lastname: Pichette
authors.forename: M
authors.initials: M
authors.lastname: Leblanc
authors.forename: A
authors.initials: A
authors.lastname: Bonnardeaux
authors.forename: D
authors.initials: D
authors.lastname: Ouimet
authors.forename: D
authors.initials: D
authors.lastname: Geadah
authors.forename: J
authors.initials: J
authors.lastname: Cardinal
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy*; D001806:Blood Urea Nitrogen; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D015312:Hemodialysis Solutions / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D010758:Phosphorus / Q000097:blood; D011188:Potassium / Q000097:blood; D006435:Renal Dialysis / Q000379:methods*; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000150:complications*; D014527:Uric Acid / Q000097:blood
chemical_list: D015312:Hemodialysis Solutions; D014527:Uric Acid; D010758:Phosphorus; D003404:Creatinine; D011188:Potassium; D002118:Calcium